Loading…
Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents
A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz porti...
Saved in:
Published in: | Royal Society open science 2022-09, Vol.9 (9), p.220358-220358 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c577t-dc1b3f6f8ef628506113655fff9ffd8d4001c782e18eefe963999e06aec6a0583 |
---|---|
cites | cdi_FETCH-LOGICAL-c577t-dc1b3f6f8ef628506113655fff9ffd8d4001c782e18eefe963999e06aec6a0583 |
container_end_page | 220358 |
container_issue | 9 |
container_start_page | 220358 |
container_title | Royal Society open science |
container_volume | 9 |
creator | Viera, Carlos R Stevens, Bradley T Viera, Talysa Zielinski, Cameron Uranga, Lee A Rogelj, Snezna Patidar, Praveen L Tello-Aburto, Rodolfo |
description | A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz portion of the cystargolide scaffold is well tolerated, producing analogues with low nanomolar proteasome inhibition activity, in many cases superior to carfilzomib. Additionally, analogue
, containing an ester and pyrazine group at Pz, was shown to possess significant activity toward RPMI 8226 cells (IC
= 21 nM) and to be less cytotoxic toward the normal tissue model MCF10A cells than carfilzomib. |
doi_str_mv | 10.1098/rsos.220358 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_9242af3164b249c0b3881f44a6e4969b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_9242af3164b249c0b3881f44a6e4969b</doaj_id><sourcerecordid>2720431840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c577t-dc1b3f6f8ef628506113655fff9ffd8d4001c782e18eefe963999e06aec6a0583</originalsourceid><addsrcrecordid>eNpVkc9LHTEQxxdpUVFPvZc9Fsra_N7kUiiPtgpCPbTnMJudrJHdzWuSV9C_vtGnoqdMMt_5ZGa-TfOBknNKjP6ScsznjBEu9UFzzIgUnewJf_cqPmrOcr4lhFBJeK_6w-aIK9r3tei4sZu7XCBNcQ4jdgNkHFtYatzCOraYC6b2-r5eYI7TDnMLud2mWBByXLAN600YQokpP-phLaFzsLpaBROuJZ827z3MGc-ezpPmz4_vvzcX3dWvn5ebb1edk31futHRgXvlNXrFtCSKUq6k9N4b70c9itq96zVDqhE9GsWNMUgUoFNApOYnzeWeO0a4tdsUFkh3NkKwjw8xTRZSCW5Ga5hg4DlVYmDCODJwrakXAhQKo8xQWV_3rO1uWHB0dY4E8xvo28wabuwU_1kjqVTMVMCnJ0CKf-vSil1CdjjPsGLcZcvq7gWnWpAq_byXuhRzTuhfvqHEPjhsHxy2e4er-uPrzl60z37y_1KeoxE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2720431840</pqid></control><display><type>article</type><title>Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents</title><source>Royal Society Open Access Journals</source><source>PubMed Central</source><creator>Viera, Carlos R ; Stevens, Bradley T ; Viera, Talysa ; Zielinski, Cameron ; Uranga, Lee A ; Rogelj, Snezna ; Patidar, Praveen L ; Tello-Aburto, Rodolfo</creator><creatorcontrib>Viera, Carlos R ; Stevens, Bradley T ; Viera, Talysa ; Zielinski, Cameron ; Uranga, Lee A ; Rogelj, Snezna ; Patidar, Praveen L ; Tello-Aburto, Rodolfo</creatorcontrib><description>A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz portion of the cystargolide scaffold is well tolerated, producing analogues with low nanomolar proteasome inhibition activity, in many cases superior to carfilzomib. Additionally, analogue
, containing an ester and pyrazine group at Pz, was shown to possess significant activity toward RPMI 8226 cells (IC
= 21 nM) and to be less cytotoxic toward the normal tissue model MCF10A cells than carfilzomib.</description><identifier>ISSN: 2054-5703</identifier><identifier>EISSN: 2054-5703</identifier><identifier>DOI: 10.1098/rsos.220358</identifier><identifier>PMID: 36177203</identifier><language>eng</language><publisher>England: The Royal Society</publisher><subject>Chemistry ; multiple myeloma ; proteasome inhibitors ; β-lactones</subject><ispartof>Royal Society open science, 2022-09, Vol.9 (9), p.220358-220358</ispartof><rights>2022 The Authors.</rights><rights>2022 The Authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c577t-dc1b3f6f8ef628506113655fff9ffd8d4001c782e18eefe963999e06aec6a0583</citedby><cites>FETCH-LOGICAL-c577t-dc1b3f6f8ef628506113655fff9ffd8d4001c782e18eefe963999e06aec6a0583</cites><orcidid>0000-0001-8806-5762</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515629/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515629/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3322,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36177203$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Viera, Carlos R</creatorcontrib><creatorcontrib>Stevens, Bradley T</creatorcontrib><creatorcontrib>Viera, Talysa</creatorcontrib><creatorcontrib>Zielinski, Cameron</creatorcontrib><creatorcontrib>Uranga, Lee A</creatorcontrib><creatorcontrib>Rogelj, Snezna</creatorcontrib><creatorcontrib>Patidar, Praveen L</creatorcontrib><creatorcontrib>Tello-Aburto, Rodolfo</creatorcontrib><title>Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents</title><title>Royal Society open science</title><addtitle>R Soc Open Sci</addtitle><description>A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz portion of the cystargolide scaffold is well tolerated, producing analogues with low nanomolar proteasome inhibition activity, in many cases superior to carfilzomib. Additionally, analogue
, containing an ester and pyrazine group at Pz, was shown to possess significant activity toward RPMI 8226 cells (IC
= 21 nM) and to be less cytotoxic toward the normal tissue model MCF10A cells than carfilzomib.</description><subject>Chemistry</subject><subject>multiple myeloma</subject><subject>proteasome inhibitors</subject><subject>β-lactones</subject><issn>2054-5703</issn><issn>2054-5703</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc9LHTEQxxdpUVFPvZc9Fsra_N7kUiiPtgpCPbTnMJudrJHdzWuSV9C_vtGnoqdMMt_5ZGa-TfOBknNKjP6ScsznjBEu9UFzzIgUnewJf_cqPmrOcr4lhFBJeK_6w-aIK9r3tei4sZu7XCBNcQ4jdgNkHFtYatzCOraYC6b2-r5eYI7TDnMLud2mWBByXLAN600YQokpP-phLaFzsLpaBROuJZ827z3MGc-ezpPmz4_vvzcX3dWvn5ebb1edk31futHRgXvlNXrFtCSKUq6k9N4b70c9itq96zVDqhE9GsWNMUgUoFNApOYnzeWeO0a4tdsUFkh3NkKwjw8xTRZSCW5Ga5hg4DlVYmDCODJwrakXAhQKo8xQWV_3rO1uWHB0dY4E8xvo28wabuwU_1kjqVTMVMCnJ0CKf-vSil1CdjjPsGLcZcvq7gWnWpAq_byXuhRzTuhfvqHEPjhsHxy2e4er-uPrzl60z37y_1KeoxE</recordid><startdate>20220928</startdate><enddate>20220928</enddate><creator>Viera, Carlos R</creator><creator>Stevens, Bradley T</creator><creator>Viera, Talysa</creator><creator>Zielinski, Cameron</creator><creator>Uranga, Lee A</creator><creator>Rogelj, Snezna</creator><creator>Patidar, Praveen L</creator><creator>Tello-Aburto, Rodolfo</creator><general>The Royal Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8806-5762</orcidid></search><sort><creationdate>20220928</creationdate><title>Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents</title><author>Viera, Carlos R ; Stevens, Bradley T ; Viera, Talysa ; Zielinski, Cameron ; Uranga, Lee A ; Rogelj, Snezna ; Patidar, Praveen L ; Tello-Aburto, Rodolfo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c577t-dc1b3f6f8ef628506113655fff9ffd8d4001c782e18eefe963999e06aec6a0583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Chemistry</topic><topic>multiple myeloma</topic><topic>proteasome inhibitors</topic><topic>β-lactones</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Viera, Carlos R</creatorcontrib><creatorcontrib>Stevens, Bradley T</creatorcontrib><creatorcontrib>Viera, Talysa</creatorcontrib><creatorcontrib>Zielinski, Cameron</creatorcontrib><creatorcontrib>Uranga, Lee A</creatorcontrib><creatorcontrib>Rogelj, Snezna</creatorcontrib><creatorcontrib>Patidar, Praveen L</creatorcontrib><creatorcontrib>Tello-Aburto, Rodolfo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Royal Society open science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Viera, Carlos R</au><au>Stevens, Bradley T</au><au>Viera, Talysa</au><au>Zielinski, Cameron</au><au>Uranga, Lee A</au><au>Rogelj, Snezna</au><au>Patidar, Praveen L</au><au>Tello-Aburto, Rodolfo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents</atitle><jtitle>Royal Society open science</jtitle><addtitle>R Soc Open Sci</addtitle><date>2022-09-28</date><risdate>2022</risdate><volume>9</volume><issue>9</issue><spage>220358</spage><epage>220358</epage><pages>220358-220358</pages><issn>2054-5703</issn><eissn>2054-5703</eissn><abstract>A series of cystargolide-based β-lactone analogues containing nitrogen atoms at the Pz portion of the scaffold were prepared and evaluated as proteasome inhibitors, and for their cytotoxicity profile toward several cancer cell lines. Inclusion of one, two or even three nitrogen atoms at the Pz portion of the cystargolide scaffold is well tolerated, producing analogues with low nanomolar proteasome inhibition activity, in many cases superior to carfilzomib. Additionally, analogue
, containing an ester and pyrazine group at Pz, was shown to possess significant activity toward RPMI 8226 cells (IC
= 21 nM) and to be less cytotoxic toward the normal tissue model MCF10A cells than carfilzomib.</abstract><cop>England</cop><pub>The Royal Society</pub><pmid>36177203</pmid><doi>10.1098/rsos.220358</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-8806-5762</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2054-5703 |
ispartof | Royal Society open science, 2022-09, Vol.9 (9), p.220358-220358 |
issn | 2054-5703 2054-5703 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_9242af3164b249c0b3881f44a6e4969b |
source | Royal Society Open Access Journals; PubMed Central |
subjects | Chemistry multiple myeloma proteasome inhibitors β-lactones |
title | Cystargolide-based amide and ester Pz analogues as proteasome inhibitors and anti-cancer agents |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cystargolide-based%20amide%20and%20ester%20Pz%20analogues%20as%20proteasome%20inhibitors%20and%20anti-cancer%20agents&rft.jtitle=Royal%20Society%20open%20science&rft.au=Viera,%20Carlos%20R&rft.date=2022-09-28&rft.volume=9&rft.issue=9&rft.spage=220358&rft.epage=220358&rft.pages=220358-220358&rft.issn=2054-5703&rft.eissn=2054-5703&rft_id=info:doi/10.1098/rsos.220358&rft_dat=%3Cproquest_doaj_%3E2720431840%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c577t-dc1b3f6f8ef628506113655fff9ffd8d4001c782e18eefe963999e06aec6a0583%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2720431840&rft_id=info:pmid/36177203&rfr_iscdi=true |